These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34628472)

  • 21. High-dose chemotherapy and peripheral hematopoietic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma.
    Kelta M; Zekri J; Abdelghany E; Rehman JU; Khan ZA; Al-Saadi R; Dada R
    Tumori; 2018 Dec; 104(6):471-475. PubMed ID: 28009428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
    Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
    Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
    Rassy E; Danu A; Ibrahim T; Lazarovici J; Ghez D; Michot JM; Arfi-Rouche J; Rossignol J; Vergé V; Dartigues P; Ribrag V
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e373-e380. PubMed ID: 33277224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation.
    Levis M; Piva C; Filippi AR; Botto B; Gavarotti P; Pregno P; Nicolosi M; Freilone R; Parvis G; Gottardi D; Vitolo U; Ricardi U
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):14-22. PubMed ID: 27727134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma.
    Kuruvilla J; Nagy T; Pintilie M; Tsang R; Keating A; Crump M
    Cancer; 2006 Jan; 106(2):353-60. PubMed ID: 16329112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peritransplant Radiation Therapy in Patients With Refractory or Relapsed Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant: Long-Term Results of a Retrospective Study of the Fondazione Italiana Linfomi.
    Levis M; Campbell BA; Matrone F; Grapulin L; Di Russo A; Buglione M; Iamundo De Cumis I; Simontacchi G; Ciammella P; Magli A; Pascale G; Meregalli S; MacManus M; Fanetti G; De Felice F; Furfaro G; Ciccone G; Ricardi U
    Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1008-1018. PubMed ID: 36822373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03).
    Wirth A; Prince HM; Roos D; Gibson J; O'Brien P; Zannino D; Khodr B; Stone JM; Davis S; Hertzberg M
    Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1158-1166. PubMed ID: 30553941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
    Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
    Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy.
    Rauf MS; Maghfoor I; Elhassan TA; Akhtar S
    Med Oncol; 2015 Jan; 32(1):388. PubMed ID: 25429839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis.
    Strati P; Cheng PTM; Steiner RE; Alcedo Andrade PE; Feng L; Sano D; Rao VA; Singh P; Miranda R; Gunther JR; Pinnix CC; Dabaja BS; Cuglievan B; Xing K; Villa D; Skinnider B; Sehn LH; Connors JM; Nieto Y; Ahmed S; Lee HJ; Savage KJ
    Br J Haematol; 2021 Feb; 192(3):560-567. PubMed ID: 33517581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
    Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
    Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Moskowitz AJ; Yahalom J; Kewalramani T; Maragulia JC; Vanak JM; Zelenetz AD; Moskowitz CH
    Blood; 2010 Dec; 116(23):4934-7. PubMed ID: 20733154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation.
    Bentolila G; Pavlovsky A
    Leuk Lymphoma; 2020 Jul; 61(7):1548-1554. PubMed ID: 32148142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Eroglu C; Kaynar L; Orhan O; Keklik M; Sahin C; Yildiz OG; Mentes S; Kurnaz F; Aslan D; Sivgin S; Soyuer S; Eser B; Cetin M; Unal A
    Am J Clin Oncol; 2015 Feb; 38(1):68-73. PubMed ID: 23563207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
    Shafey M; Duan Q; Russell J; Duggan P; Balogh A; Stewart DA
    Leuk Lymphoma; 2012 Apr; 53(4):596-602. PubMed ID: 21929284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.
    Villa D; Seshadri T; Puig N; Massey C; Tsang R; Keating A; Crump M; Kuruvilla J
    Haematologica; 2012 May; 97(5):751-7. PubMed ID: 22180434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies.
    Viviani S; Vanazzi A; Frassoni S; Rusconi C; Rossi A; Romano A; Patti C; Schiavotto C; Sorasio R; Marasco V; Lissandrini L; Rapezzi D; Gottardi D; Cocito F; Mulè A; Leotta S; Gini G; Sorio M; Derenzini E; Rambaldi A; Bagnardi V; Tarella C
    Leuk Lymphoma; 2024 Apr; 65(4):460-471. PubMed ID: 38164812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
    Poiré X; Kline J; Grinblatt D; Zimmerman T; Conner K; Muhs C; Gajewski T; Van Besien K; Smith SM
    Leuk Lymphoma; 2010 Jul; 51(7):1241-50. PubMed ID: 20496994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
    Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U
    Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.